SCHEMBL4674497

SCHEMBL4674497

O=C(O)/C(O)=C/C(=O)c1ccn(Cc2ccccc2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.47
AKR1B1 P15121 1/20 0.42
KLKB1 P03952 1/20 0.41
CA12 O43570 2/20 0.40
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40
CA9 Q16790 2/20 0.40
CYP19A1 P11511 3/20 0.37
KDM5A P29375 1/20 0.36
KDM4C Q9H3R0 1/20 0.36
KDM5B Q9UGL1 1/20 0.36
POLB P06746 2/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
NFE2L2 Q16236 1/20 0.35
HDAC1 Q13547 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4674501 1.00 CYP2C19 (0.47) CYP2C19AKR1B1KLKB1CA12CA1
SCHEMBL4676600 0.87 KLKB1 (0.37) CYP2C19AKR1B1KLKB1CA12CA1
SCHEMBL4676603 0.87 KLKB1 (0.37) CYP2C19AKR1B1KLKB1CA12CA1
SCHEMBL4678121 0.87 CYP11B1 (0.40) CYP2C19KLKB1CYP19A1POLBKDM4E
SCHEMBL4671698 0.87 CA12 (0.43) CYP2C19CA12CA1CA2CA9
SCHEMBL4677417 0.87 KLKB1 (0.37) CYP2C19KLKB1CYP19A1POLBKDM4E
SCHEMBL4671701 0.87 CA12 (0.43) CYP2C19CA12CA1CA2CA9
SCHEMBL4677414 0.87 KLKB1 (0.37) CYP2C19KLKB1CYP19A1POLBKDM4E
SCHEMBL4678115 0.87 CYP11B1 (0.40) CYP2C19KLKB1CYP19A1POLBKDM4E
SCHEMBL4673031 0.86 KMT2A (0.39) CYP2C19KLKB1CYP19A1HDAC1TBXAS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 CYP2C19 53/4885AKR1B1 17/4885KLKB1 3843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.